CL2017000498A1 - Una formulación de n-acetilgalactosamina-6-sulfatasa humana activa altamente fosforida (galns)(divisional solicitud 219-2013) - Google Patents

Una formulación de n-acetilgalactosamina-6-sulfatasa humana activa altamente fosforida (galns)(divisional solicitud 219-2013)

Info

Publication number
CL2017000498A1
CL2017000498A1 CL2017000498A CL2017000498A CL2017000498A1 CL 2017000498 A1 CL2017000498 A1 CL 2017000498A1 CL 2017000498 A CL2017000498 A CL 2017000498A CL 2017000498 A CL2017000498 A CL 2017000498A CL 2017000498 A1 CL2017000498 A1 CL 2017000498A1
Authority
CL
Chile
Prior art keywords
galns
formulation
sulfatase
acetylgalactosamine
divisional application
Prior art date
Application number
CL2017000498A
Other languages
English (en)
Inventor
Vish Koppaka
Michel Claude Vellard
Kidisti Araya
Augustus O Okhamafe
Original Assignee
Biomarin Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomarin Pharm Inc filed Critical Biomarin Pharm Inc
Publication of CL2017000498A1 publication Critical patent/CL2017000498A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/06—Sulfuric ester hydrolases (3.1.6)
    • C12Y301/06004—N-Acetylgalactosamine-6-sulfatase (3.1.6.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

<p>UNA FORMULACIÓN QUE INCLUYE DICHA ENZIMA (GALNS) ÚTIL PARA EL DIAGNÓSTICO, PROFILAXIS O TRATAMIENTO DE ENFERMEDADES Y CONDICIONES, CAUSADAS POR ALMACENAMIENTO LISOSOMAL O ASOCIADAS CON UNA DEFICIENCIA EN LA ENZIMA GALNS, POR EJEMPLO, LA MUCOPOLISACARIDOSIS IVa (MPS IVa O SÍNDROME DE MORQUIO A).</p>
CL2017000498A 2010-07-22 2017-03-02 Una formulación de n-acetilgalactosamina-6-sulfatasa humana activa altamente fosforida (galns)(divisional solicitud 219-2013) CL2017000498A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US36671410P 2010-07-22 2010-07-22

Publications (1)

Publication Number Publication Date
CL2017000498A1 true CL2017000498A1 (es) 2017-11-24

Family

ID=44543776

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2013000219A CL2013000219A1 (es) 2010-07-22 2013-01-22 Método para la purificación de una n-acetilgalactosamina-6-sulfatasa humana activa altamente fosforilada (galns); composición purificada que comprende galns; método para la prevención de la desfosforilación de una enzima galns.
CL2017000498A CL2017000498A1 (es) 2010-07-22 2017-03-02 Una formulación de n-acetilgalactosamina-6-sulfatasa humana activa altamente fosforida (galns)(divisional solicitud 219-2013)

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CL2013000219A CL2013000219A1 (es) 2010-07-22 2013-01-22 Método para la purificación de una n-acetilgalactosamina-6-sulfatasa humana activa altamente fosforilada (galns); composición purificada que comprende galns; método para la prevención de la desfosforilación de una enzima galns.

Country Status (28)

Country Link
US (3) US8765437B2 (es)
EP (1) EP2595650B1 (es)
JP (2) JP6030553B2 (es)
KR (2) KR101598897B1 (es)
CN (1) CN103037895B (es)
AR (2) AR082319A1 (es)
AU (1) AU2011280937B2 (es)
BR (1) BR112013001558B1 (es)
CA (2) CA3146151A1 (es)
CL (2) CL2013000219A1 (es)
CY (1) CY1118934T1 (es)
DK (1) DK2595650T3 (es)
ES (1) ES2616263T3 (es)
HR (1) HRP20170245T1 (es)
HU (1) HUE033163T2 (es)
IL (2) IL224125B (es)
LT (1) LT2595650T (es)
MX (1) MX341838B (es)
PE (3) PE20171798A1 (es)
PL (1) PL2595650T3 (es)
PT (1) PT2595650T (es)
RS (1) RS55669B1 (es)
RU (1) RU2607376C2 (es)
SG (1) SG187580A1 (es)
SI (1) SI2595650T1 (es)
SM (2) SMT201700106T1 (es)
WO (1) WO2012012718A2 (es)
ZA (1) ZA201300286B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2711590C (en) * 2008-01-18 2021-03-23 Biomarin Pharmaceutical Inc. Manufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses thereof
US8956859B1 (en) 2010-08-13 2015-02-17 Aviex Technologies Llc Compositions and methods for determining successful immunization by one or more vaccines
US20130202633A1 (en) * 2012-02-07 2013-08-08 Saint Louis University, A Non-Profit Organization Determination of immunogenic peptides in lysosomal enzymes and induction of oral tolerance
KR101380740B1 (ko) 2012-06-29 2014-04-11 쉐어 휴먼 제네텍 세러피스, 인코포레이티드 이듀로네이트-2-설파타제의 정제
US11529397B2 (en) 2018-01-22 2022-12-20 Saint Louis University Method of treating mucopolysaccharidosis type IVA
DK2968494T3 (en) * 2013-03-13 2019-03-04 Seattle Genetics Inc ACTIVATED CARBON FILTERING FOR CLEANING BENZODIAZEPINE ADCs
JP2016518113A (ja) * 2013-03-13 2016-06-23 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド リソソーム系酵素の特性評価の方法
CN115120746A (zh) 2013-05-15 2022-09-30 明尼苏达大学董事会 腺相关病毒介导的基因向中枢神经系统转移
WO2014201220A1 (en) * 2013-06-12 2014-12-18 The Board Of Trustees Of The University Of Illinois Methods for detecting prostate cancer
US9910041B2 (en) 2013-07-12 2018-03-06 Emd Millipore Corporation Method of determining virus removal from a sample containing a target protein using activated carbon
EP3166626B1 (en) * 2014-07-11 2021-04-28 Biostrategies LC Materials and methods for treating disorders associated with sulfatase enzymes
US10472615B2 (en) 2016-01-21 2019-11-12 Saint Louis University Reduced immunogenic proteins for lysosomal storage disorders
JP2019515677A (ja) 2016-04-26 2019-06-13 アール．ピー．シェーラー テクノロジーズ エルエルシー 抗体複合体ならびにそれを作製および使用する方法
EP3676375A4 (en) * 2017-08-31 2021-04-07 Green Cross Corporation PROCESS FOR PURIFYING A SULFATASE PROTEIN
MX2020012911A (es) * 2018-05-30 2021-02-26 Esteve Pharmaceuticals Sa Vectores de virus adenoasociados para el tratamiento de mucopolisacaridosis tipo iv a.
RU2763990C2 (ru) * 2020-02-19 2022-01-12 Акционерное общество "ГЕНЕРИУМ" Клетка, продуцирующая с высокой эффективностью активный белок арилсульфатазу в, и способ получения этой клетки
US20230193205A1 (en) * 2020-04-19 2023-06-22 Figene, Llc Gene modified fibroblasts for therapeutic applications
WO2023150387A1 (en) * 2022-02-07 2023-08-10 M6P Therapeutics, Inc. Compositions comprising acid alpha glucosidase and methods of use thereof
TW202403043A (zh) * 2022-03-18 2024-01-16 美商健臻公司 重組人類酸性鞘磷脂酶醫藥組合物及方法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4394448A (en) 1978-02-24 1983-07-19 Szoka Jr Francis C Method of inserting DNA into living cells
US4391904A (en) 1979-12-26 1983-07-05 Syva Company Test strip kits in immunoassays and compositions therein
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US5186941A (en) 1983-05-06 1993-02-16 Vestar, Inc. Vesicle formulation for the controlled release of therapeutic agents
JPS62122588A (ja) 1985-11-22 1987-06-03 Taiyo Fishery Co Ltd 純コンドロイチナ−ゼの製造法
US6048729A (en) 1987-05-01 2000-04-11 Transkaryotic Therapies, Inc. In vivo protein production and delivery system for gene therapy
PT101031B (pt) 1991-11-05 2002-07-31 Transkaryotic Therapies Inc Processo para o fornecimento de proteinas por terapia genetica
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
TW492882B (en) 1997-11-28 2002-07-01 Caleb Pharmaceuticals Inc Cholinergic antagonist plaster composition
US6689600B1 (en) * 1998-11-16 2004-02-10 Introgen Therapeutics, Inc. Formulation of adenovirus for gene therapy
US7083793B2 (en) 1999-02-26 2006-08-01 Millennium Pharmaceuticals, Inc. Tango 243 polypeptides and uses thereof
US6534300B1 (en) 1999-09-14 2003-03-18 Genzyme Glycobiology Research Institute, Inc. Methods for producing highly phosphorylated lysosomal hydrolases
US6261595B1 (en) 2000-02-29 2001-07-17 Zars, Inc. Transdermal drug patch with attached pocket for controlled heating device
RU2195492C2 (ru) * 2000-09-04 2002-12-27 Институт физиологии Коми научного центра Уральского отделения РАН Способ получения пектолитического ферментного препарата
DK1395669T3 (da) 2001-01-26 2009-11-16 Selexis Sa Matriks bindingsregioner og fremgangsmåder til anvendelse af disse
US7332304B2 (en) * 2002-07-01 2008-02-19 Arkion Life Sciences Llc Process and materials for production of glucosamine and N-acetylglucosamine
CA2515708A1 (en) 2003-02-11 2004-08-26 Transkaryotic Therapies, Inc. Diagnosis and treatment of multiple sulfatase deficiency and other sulfatase deficiencies
JP2007277094A (ja) * 2004-06-29 2007-10-25 Chemo Sero Therapeut Res Inst 改変ダニ主要アレルゲン含有医薬組成物
EP1836316A4 (en) * 2004-12-22 2009-07-22 Ambrx Inc PROCESS FOR EXPRESSION AND CLEANING OF RECOMBINANT HUMAN GROWTH HORMONE
AU2007240732B2 (en) * 2006-04-21 2013-07-04 Amgen, Inc. Buffering agents for biopharmaceutical formulations
US20080231439A1 (en) 2007-03-22 2008-09-25 Inventec Corporation Activity Detection Circuit for a Storage Device
US8420081B2 (en) * 2007-11-30 2013-04-16 Abbvie, Inc. Antibody formulations and methods of making same
US7722865B2 (en) * 2008-01-18 2010-05-25 Biomarin Pharmaceutical Inc. Manufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses thereof
CA2711590C (en) * 2008-01-18 2021-03-23 Biomarin Pharmaceutical Inc. Manufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses thereof
EP2196476A1 (en) * 2008-12-10 2010-06-16 Novartis Ag Antibody formulation

Also Published As

Publication number Publication date
EP2595650B1 (en) 2016-11-16
ZA201300286B (en) 2014-03-26
BR112013001558A2 (pt) 2020-08-04
BR112013001558B1 (pt) 2022-08-16
CA3146151A1 (en) 2012-01-26
PE20171799A1 (es) 2017-12-28
JP2013532986A (ja) 2013-08-22
US8940513B2 (en) 2015-01-27
RS55669B1 (sr) 2017-06-30
US20160186149A1 (en) 2016-06-30
KR20150038715A (ko) 2015-04-08
CA2805673A1 (en) 2012-01-26
US20120189605A1 (en) 2012-07-26
EP2595650A2 (en) 2013-05-29
HRP20170245T1 (hr) 2017-04-21
ES2616263T3 (es) 2017-06-12
IL224125B (en) 2019-02-28
KR101949906B1 (ko) 2019-04-22
DK2595650T3 (en) 2017-02-27
PL2595650T3 (pl) 2017-06-30
CL2013000219A1 (es) 2014-07-11
WO2012012718A2 (en) 2012-01-26
US20140341878A1 (en) 2014-11-20
SG187580A1 (en) 2013-03-28
SMT201700106T1 (it) 2017-03-08
AR119552A2 (es) 2021-12-29
AU2011280937B2 (en) 2016-06-09
SMT201700106B (it) 2017-03-08
KR20130105605A (ko) 2013-09-25
IL260282A (en) 2018-07-31
IL260282B (en) 2020-05-31
JP6030553B2 (ja) 2016-11-24
KR101598897B1 (ko) 2016-03-03
SI2595650T1 (sl) 2017-04-26
MX341838B (es) 2016-09-05
CN103037895A (zh) 2013-04-10
HUE033163T2 (en) 2017-11-28
AU2011280937A1 (en) 2013-01-31
PT2595650T (pt) 2017-02-22
WO2012012718A3 (en) 2012-04-05
US9567572B2 (en) 2017-02-14
AR082319A1 (es) 2012-11-28
LT2595650T (lt) 2017-03-10
CY1118934T1 (el) 2018-01-10
CA2805673C (en) 2022-04-05
RU2607376C2 (ru) 2017-01-10
RU2013107765A (ru) 2014-08-27
PE20131140A1 (es) 2013-10-17
PE20171798A1 (es) 2017-12-28
US8765437B2 (en) 2014-07-01
CN103037895B (zh) 2016-11-09
MX2013000908A (es) 2013-07-05
JP2016178950A (ja) 2016-10-13

Similar Documents

Publication Publication Date Title
CL2017000498A1 (es) Una formulación de n-acetilgalactosamina-6-sulfatasa humana activa altamente fosforida (galns)(divisional solicitud 219-2013)
MX2010007846A (es) Fabricación de enzimas sulfatasa lisosomal humana altamente fosforilada, activa y usos de las mismas.
ES2544967T3 (es) Formulación y método para la prevención y el tratamiento de las metástasis óseas o de otras enfermedades óseas
CL2020000468A1 (es) Uso de una formulación estable que comprende una enzima de reemplazo para la enzima lisosomal (divisional solicitud 201801220)
MX2019000547A (es) Formulaciones de adamts13 liquidas y liofilizadas, estabilizadas.
MX2020002867A (es) Inhibidores de glucosilceramida sintasa.
CL2016001553A1 (es) Medios para cultivo celular
BR112014031874A2 (pt) método para preparar células-tronco em concentração elevada
BRPI0906549A2 (pt) Bandagens médicas com válvulas e kits contendo as mesmas.
ECSP13012978A (es) Inhibidores de glucosilceramida sintasa
CO6571886A2 (es) Antagonistas de pcsk9
BR112015013349A2 (pt) trieptanoína para o tratamento de deficiência de transportador de glicose 1
CL2010000829A1 (es) Metodo para tratar plantas que comprende aplicar a las plantas una composicion liquida que contiene ente 0,3 a 300 miligramos de uno o mas ciclopropenos por litro de dicha composicion.
BR112012007798A2 (pt) microcápsulas estáveis e composição para aplicação tópica e método para a preparação de microcápsulas
UA113188C2 (xx) Спосіб одержання гідрогелю з використанням ферментів ліпаз
BR112012019920A2 (pt) derivados de piridazina úteis como agonístas de canabinoide-2.
BRPI0700133A (pt) composição farmacêutica compreendendo tramadol e cetoprofeno em combinação
CL2010001594A1 (es) Uso de nifurtimox para preparar un medicamento útil en el tratamiento de enfermedades causadas por trichomonadida.
WO2011103458A3 (en) Compositions and methods for using and identifying antimicrobial agents
MX2021008091A (es) Composicion que comprende artropodos y huevos de acaros astigmatidos.
PH12014501307A1 (en) Liquid activation system
ITMI20052515A1 (it) Formulazione farmaceutica per il trattamento della osteoartrite
RU2009136584A (ru) Растительное антгельминтное средство
AR118157A2 (es) Una enzima n-acetilgalactosamina-6-sulfatasa (galns) humana recombinante, composición y sus usos
MX2016010719A (es) Ensayos de aclaramiento de sustratos para enzimas lisosomales.